Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Gastric cancer
Pharmacokinetics
S-1
Watering eyes
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
10
10
2018
accepted:
19
12
2018
pubmed:
24
4
2019
medline:
28
7
2019
entrez:
24
4
2019
Statut:
ppublish
Résumé
S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Recently, some studies have been reported on watering eyes caused by S-1. However, the mechanism of watering eyes caused by S-1 is still unclear. The aim of this study was to investigate the correlation between tears and plasma concentrations of FT, 5-FU, and CDHP, which are components and active modulator of S-1. We prospectively investigated the pharmacokinetics (PK) of FT, 5-FU, and CDHP in plasma and in tears of gastric cancer patients who were treated with S-1 monotherapy at the dose of 80 mg/m Total of eight patients were enrolled. All the FT, 5-FU and CDHP were detected both in plasma and in tears, and their PK parameters were measured. There was a positive correlation between the concentrations of FT, 5-FU and CDHP in the plasma and those in the tears on day 1 and day 14 (correlation coefficients r, right eye/left eye: r = 0.882/0.878, 0.877/0.890, and 0.885/0.878, respectively). There was a positive correlation between the concentrations of FT, 5-FU and CDHP in the plasma and those in the tears. The result is expected to facilitate the further investigation into the causes of watering eyes and the establishment of the effective methods for the prevention and the treatment.
Sections du résumé
BACKGROUND
BACKGROUND
S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Recently, some studies have been reported on watering eyes caused by S-1. However, the mechanism of watering eyes caused by S-1 is still unclear. The aim of this study was to investigate the correlation between tears and plasma concentrations of FT, 5-FU, and CDHP, which are components and active modulator of S-1.
METHODS
METHODS
We prospectively investigated the pharmacokinetics (PK) of FT, 5-FU, and CDHP in plasma and in tears of gastric cancer patients who were treated with S-1 monotherapy at the dose of 80 mg/m
RESULTS
RESULTS
Total of eight patients were enrolled. All the FT, 5-FU and CDHP were detected both in plasma and in tears, and their PK parameters were measured. There was a positive correlation between the concentrations of FT, 5-FU and CDHP in the plasma and those in the tears on day 1 and day 14 (correlation coefficients r, right eye/left eye: r = 0.882/0.878, 0.877/0.890, and 0.885/0.878, respectively).
CONCLUSION
CONCLUSIONS
There was a positive correlation between the concentrations of FT, 5-FU and CDHP in the plasma and those in the tears. The result is expected to facilitate the further investigation into the causes of watering eyes and the establishment of the effective methods for the prevention and the treatment.
Identifiants
pubmed: 31011915
doi: 10.1007/s10147-018-01387-6
pii: 10.1007/s10147-018-01387-6
pmc: PMC6525142
doi:
Substances chimiques
5-chlorodihydroxypyridine
0
Drug Combinations
0
Pyridines
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Pagination
660-665Références
Ophthalmic Plast Reconstr Surg. 2003 May;19(3):216-24
pubmed: 12918558
Am J Ophthalmol. 2005 Aug;140(2):325-7
pubmed: 16086962
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Gan To Kagaku Ryoho. 2010 Sep;37(9):1639-44
pubmed: 20841924
Gan To Kagaku Ryoho. 2011 Feb;38(2):259-62
pubmed: 21368490
Jpn J Ophthalmol. 2012 May;56(3):214-8
pubmed: 22411166
Ann Oncol. 2012 Aug;23(8):2065-71
pubmed: 22589332
Ann Oncol. 2015 Jan;26(1):141-8
pubmed: 25316259
Gastric Cancer. 2016 Jul;19(3):894-901
pubmed: 26362271
Cancer Res Treat. 2018 Jan;50(1):30-39
pubmed: 28253565
J Toxicol Sci. 2017;42(3):291-300
pubmed: 28496035